Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of SORT1, the target for Theratechnologies’ oncology platform, in several cancer types.
Read MoreMerger includes C$20 million investment to accelerate access to genomics-based testing for cancer treatment by combining Canexia Health’s advanced molecular cancer solutions with Imagia Cybernetics’ healthcare and AI expertise
Read More